Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 169
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Contraception ; 119: 109917, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36473512

RESUMEN

OBJECTIVES: In this study, I examined the low uptake of oral contraceptives (OCs) in China and the factors affecting the reluctance among unmarried Chinese women seeking abortion to use OCs to prevent unintended pregnancies. STUDY DESIGN: I conducted ethnographic and participant observation in multiple medical facilities and interviewed 62 women who were seeking or had had an abortion between 2013 and 2017 in a coastal city in east China. I analyzed data regarding the women's perceptions and experiences of using OCs through a thematic analysis approach. RESULTS: The women reported fear of side effects, including infertility, weight gain, and mental health issues and their view on traditional Chinese medicine further validated their skepticism toward Western medicine. Discouragement from male partners and a lack of sexual and reproductive education also caused their hesitancy and misunderstandings of OCs. CONCLUSIONS: This study contributes to a more nuanced understanding of the barriers to OC use in China. It resonates with existing studies that associate the reluctance to use OCs with the fear of side effects and highlights the influence of sociocultural specificities and couple interactions in shaping contraceptive use. IMPLICATIONS: Tackling premarital abortions is one of the priorities of the Chinese government in the face of the population crisis. Service providers and educators should understand unmarried women's reluctance to use OCs and provide comprehensive sexuality education and postabortion counseling services to women and men to dispel culturally specific misconceptions.


Asunto(s)
Aborto Inducido , Anticonceptivos Orales , Embarazo , Humanos , Masculino , Femenino , Anticonceptivos Orales/efectos adversos , Persona Soltera , Servicios de Planificación Familiar , China , Anticoncepción
2.
Ann Nutr Metab ; 77(4): 231-235, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34350850

RESUMEN

OBJECTIVE: Similar to pregnant women, women taking an oral contraceptive (OC) might have elevated iodine requirements due to the altered hormonal state. This is the first study aimed at investigating the prevalence of iodine deficiency and possible influences of OC intake on urine creatinine and iodine levels in young women. METHODS: One hundred fifty-five women between the age of 18 and 35 years (62 taking an OC and 93 controls) participated in a cross-sectional pilot study at the Medical University of Vienna, which included a 1-spot urine sample and a questionnaire on OC intake as well as a food questionnaire. RESULTS: The median urinary iodine concentration (UIC) in this study was 68 µg/L (41, 111 µg/L) suggesting an inadequate iodine status in the women according to the WHO guidelines. Median UIC (OC: 89 µg/L, IQR 55-120; control: 59 µg/L, IQR 39-91, p = 0.010) and urine creatinine (OC: median = 99.0 µg/L, IQR 74.9-175.5; control: 77.0 µg/L, IQR 49.6-147.2, p = 0.030) levels were significantly higher in OC women than in the control group. UIC corrected for urine creatinine was comparable between both groups. CONCLUSION: With similar creatinine-corrected UICs in both groups, OC intake might not have a significant impact on iodine status. However, the low median UIC in a vulnerable group of young women potentially conceiving in the following years points at the necessity of optimizing the iodine intake in the Austrian population and reiterates the insufficiency of the current iodine supplementation measures.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Yodo/deficiencia , Yodo/orina , Adolescente , Austria/epidemiología , Anticonceptivos Orales/administración & dosificación , Creatinina/orina , Estudios Transversales , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/orina , Femenino , Humanos , Estado Nutricional , Proyectos Piloto , Embarazo , Prevalencia , Adulto Joven
3.
BMJ Case Rep ; 12(11)2019 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-31748351

RESUMEN

This is a case report of a 48-year-old woman who presented with heavy per vaginal bleeding to the emergency department after being commenced on direct oral anticoagulants (DOACs) for venous thromboembolism. She had significant bleeding which initially required resuscitation and stabilisation. Her symptoms were ultimately managed by changing her anticoagulation agent to therapeutic low molecular weight heparin with Clexane© the agent of choice. This case study highlights the complexity of managing these patients as well as highlighting the need for ongoing research into DOACs in this area.


Asunto(s)
Anticoagulantes/efectos adversos , Hemorragia Uterina/inducido químicamente , Tromboembolia Venosa/tratamiento farmacológico , Administración Oral , Anticonceptivos Orales/efectos adversos , Diagnóstico Diferencial , Enoxaparina/uso terapéutico , Inhibidores del Factor Xa/efectos adversos , Inhibidores del Factor Xa/uso terapéutico , Femenino , Fibrinolíticos/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Persona de Mediana Edad , Rivaroxabán/efectos adversos , Rivaroxabán/uso terapéutico , Resultado del Tratamiento , Hemorragia Uterina/tratamiento farmacológico , Tromboembolia Venosa/inducido químicamente
4.
Medicine (Baltimore) ; 98(35): e16996, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31464951

RESUMEN

RATIONALE: Hormone imbalance and menstrual irregularities are normal for postpill women. Pharmacopuncture and moxibustion can stimulate acupoints with herbal extract and heat, respectively, to regulate the function of qi and blood, expel pathogens, and support health. PATIENT CONCERNS: A 39-year-old female patient presented with amenorrhea, >6 months after she had stopped taking the oral contraceptive pill, which she had taken for more than 10 years, and possible associated infertility. Additionally, she reported sudden weight gain of approximately 12 kg in 1 year. DIAGNOSES: In this study, we examined the amenorrhea lasted more than 6 months for postpill patient. INTERVENTIONS: She refused a strong acupuncture stimulus; she underwent lower abdomen pharmacopuncture with wild ginseng complex (WGC) and moxibustion at CV4, 5 times during 1 month. As a secondary treatment, 1 g Geoseub-hwan pills were prescribed for overeating and during social events. After 5 weekly primary treatments, Geoseub-hwan was prescribed intermittently. OUTCOME: After 3 primary treatments, she began menstruation without menstrual cramps or discomfort. After 5 treatments, she exhibited improvement of body weight and body composition. At 1- and 3-month follow-up examinations, she confirmed regular menstruation without discomfort. LESSONS: Pharmacopuncture with WGC and moxibustion may be effective for the treatment of postpill amenorrhea with abdominal obesity and can be used for patients with fear of a strong acupuncture stimulus.


Asunto(s)
Terapia por Acupuntura/métodos , Amenorrea/terapia , Medicina Tradicional Coreana/métodos , Adulto , Amenorrea/etiología , Terapia Combinada , Anticonceptivos Orales/efectos adversos , Femenino , Humanos , Moxibustión/métodos , Panax , República de Corea , Aumento de Peso
5.
Intern Med ; 58(10): 1507-1509, 2019 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-30713291

RESUMEN

We herein report a teenage girl who had been taking oral contraceptive pills for three months and complained of left lower abdominal pain that had continued for two months. A physical examination indicated anterior cutaneous nerve entrapment syndrome (ACNES), although no abnormality was found in various biochemical and imaging examinations. The pain was only transiently ameliorated by trigger-point injection, and neurectomy surgery was eventually effective. Sex steroids can be involved in the progress of local tissue edema causing ACNES. ACNES should be considered in cases of abdominal pain in patients taking oral contraceptives.


Asunto(s)
Dolor Abdominal/etiología , Dolor Abdominal/cirugía , Anticonceptivos Orales/efectos adversos , Desnervación/métodos , Síndromes de Compresión Nerviosa/inducido químicamente , Síndromes de Compresión Nerviosa/cirugía , Adolescente , Femenino , Humanos , Resultado del Tratamiento
6.
Sci Rep ; 7(1): 14111, 2017 10 26.
Artículo en Inglés | MEDLINE | ID: mdl-29074884

RESUMEN

Using oral contraceptives has been implicated in the aetiology of stress-related disorders like depression. Here, we followed the hypothesis that oral contraceptives deregulate the HPA-axis by elevating circulating cortisol levels. We report for a sample of 233 pre-menopausal women increased circulating cortisol levels in those using oral contraceptives. For women taking oral contraceptives, we observed alterations in circulating phospholipid levels and elevated triglycerides and found evidence for increased glucocorticoid signalling as the transcript levels of the glucocorticoid-regulated genes DDIT4 and FKBP5 were increased in whole blood. The effects were statistically mediated by cortisol. The associations of oral contraceptives with higher FKBP5 mRNA and altered phospholipid levels were modified by rs1360780, a genetic variance implicated in psychiatric diseases. Accordingly, the methylation pattern of FKBP5 intron 7 was altered in women taking oral contraceptives depending on the rs1360780 genotype. Moreover, oral contraceptives modified the association of circulating cortisol with depressive symptoms, potentially explaining conflicting results in the literature. Finally, women taking oral contraceptives displayed smaller hippocampal volumes than non-using women. In conclusion, the integrative analyses of different types of physiological data provided converging evidence indicating that oral contraceptives may cause effects analogous to chronic psychological stressors regarding the regulation of the HPA axis.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Hipotálamo/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Estrés Psicológico/inducido químicamente , Adulto , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Femenino , Humanos , Intrones/genética , Imagen por Resonancia Magnética , Persona de Mediana Edad , Tamaño de los Órganos/efectos de los fármacos , Fosfolípidos/sangre , Receptores de Glucocorticoides/metabolismo , Transducción de Señal/efectos de los fármacos , Estrés Psicológico/sangre , Estrés Psicológico/genética , Estrés Psicológico/fisiopatología , Proteínas de Unión a Tacrolimus/genética , Proteínas de Unión a Tacrolimus/metabolismo , Triglicéridos/sangre , Adulto Joven
7.
PLoS One ; 11(6): e0158177, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27348598

RESUMEN

This study addressed the associations between oral contraceptive (OC) use and obesity as measured by recording the body mass index (BMI) of premenopausal females, and possible interactions with micronutrient intake were considered. A group of 39,189 premenopausal females aged 35-59 were included in the analysis; they were in the Health Examinee cohort. Participant BMIs were calculated from anthropometric measurements, and females with a BMI≥25kg/m2 were considered obese. Individual OC use, age at first OC use, duration of OC use, nutrient intake, and other covariates were measured with a structured questionnaire. A multivariate logistic regression with an interaction term was applied to identify the odds ratio (OR) and 95% confidence intervals (CI) between OC use and obesity along with consideration of micronutrient intake interactions. OC use is associated with an increased risk of obesity (OR = 1.12, 95% CI = 1.04-1.20), and females who used OCs for more than 6 months over their lifetimes were more likely to be obese (OR = 1.15, 95% CI = 1.01-1.32) compared with those who used OCs for <6 months. There were interaction effects between phosphorus, potassium, vitamin A, vitamin B1, vitamin B2, niacin, vitamin C intake and total duration of OC use on being obesity (P-value<0.05). When stratified by micronutrient intake, the associations between total OC use duration and obesity were present only among those with calcium, phosphorus, potassium, vitamin A, B1, B2, C, niacin, and folate intakes below the recommended levels. Efforts to estimate nutrient intake and prevent micronutrient depletion with supplements or food should be considered by clinicians for females who take OC for a long period.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Micronutrientes/deficiencia , Obesidad/epidemiología , Obesidad/etiología , Vigilancia de la Población , Premenopausia , Adulto , Anciano , Suplementos Dietéticos , Conducta Alimentaria , Femenino , Humanos , Persona de Mediana Edad , Oportunidad Relativa , República de Corea/epidemiología
8.
Am J Clin Nutr ; 102(3): 616-25, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26201817

RESUMEN

BACKGROUND: Low chronic vitamin B-6 status can occur in a subset of women who use oral contraceptives (OCs) with uncertain metabolic consequences. An insufficiency of cellular pyridoxal 5'-phosphate (PLP), which is the coenzyme form of vitamin B-6, may impair many metabolic processes including one-carbon and tryptophan metabolism. OBJECTIVE: We investigated the effects of vitamin B-6 supplementation on the in vivo kinetics of one-carbon metabolism and the concentration of one-carbon and tryptophan metabolites in vitamin B-6-deficient OC users. DESIGN: A primed, constant infusion of [(13)C5]methionine, [3-(13)C]serine, and [(2)H3]leucine was performed on 10 OC users (20-40 y old; plasma PLP concentrations <30 nmol/L) before and after 28 d of supplementation with 10 mg pyridoxine hydrochloric acid/d. In vivo fluxes of total homocysteine remethylation, the remethylation of homocysteine from serine, and rates of homocysteine and cystathionine production were assessed. Targeted metabolite profiling was performed, and data were analyzed by using orthogonal partial least-squares-discriminant analysis and paired t tests adjusted for multiple testing. RESULTS: Pyridoxine supplementation increased the mean ± SD plasma PLP concentration from 25.8 ± 3.6 to 143 ± 58 nmol/L (P < 0.001) and decreased the leucine concentration from 103 ± 17 to 90 ± 20 nmol/L (P = 0.007) and glycine concentration from 317 ± 63 to 267 ± 58 nmol/L (P = 0.03). Supplementation did not affect in vivo rates of homocysteine remethylation or the appearance of homocysteine and cystathionine. A multivariate analysis showed a clear overall effect on metabolite profiles resulting from supplementation. Leucine, glycine, choline, cysteine, glutathione, trimethylamine N-oxide, and the ratios glycine:serine, 3-hydroxykynurenine:kynurenine, 3-hydroxykynurenine:3-hydroxyanthranilic acid, and 3-hydroxykynurenine:anthranilic acid were significant discriminating variables. CONCLUSIONS: Consistent with previous vitamin B-6-restriction studies, fluxes of one-carbon metabolic processes exhibited little or no change after supplementation in low-vitamin B-6 subjects. In contrast, changes in the metabolic profiles after supplementation indicated perturbations in metabolism, suggesting functional vitamin B-6 deficiency. This study was registered at clinicaltrials.gov as NCT01128244.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Piridoxina/administración & dosificación , Piridoxina/sangre , Triptófano/sangre , Deficiencia de Vitamina B 6/sangre , Ácido 3-Hidroxiantranílico/metabolismo , Adulto , Biomarcadores/sangre , Carbono/metabolismo , Anticonceptivos Orales/administración & dosificación , Cistationina/sangre , Suplementos Dietéticos , Femenino , Glicina/sangre , Homocisteína/sangre , Humanos , Quinurenina/análogos & derivados , Quinurenina/sangre , Leucina/sangre , Metionina/sangre , Metilaminas/sangre , Análisis Multivariante , Fosfato de Piridoxal/sangre , Serina/sangre , Deficiencia de Vitamina B 6/etiología , Adulto Joven
9.
Ann Med ; 47(3): 253-62, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25906790

RESUMEN

INTRODUCTION: We studied prevalence of hypovitaminosis D, its determinants, and whether achievement of recommended dietary vitamin D intake (10 µg/d) is associated with absence of hypovitaminosis D in adults. METHODS: The study is part of the Cardiovascular Risk in Young Finns Study. We collected serum samples of 25-hydroxyvitamin D as part of the 27-year follow-up (994 men and 1,210 women aged 30-45 years). Hypovitaminosis was defined as vitamin D concentration ≤ 50 nmol/L. RESULTS: Hypovitaminosis D was found in 38% of men and 34% of women. Dietary vitamin D intake (OR 0.90, 95% CI 0.86-0.93), use of vitamin-mineral supplements (0.66, 0.51-0.85), sunny holiday (0.55, 0.41-0.75), and oral contraceptive use in women (0.45, 0.27-0.75) were independently associated with reduced odds of hypovitaminosis. Increase in body mass index (1.06, 1.03-1.09), being a smoker (1.36, 0.97-1.92), investigation month (December versus other) (1.35, 1.12-1.61), and risk alleles in genotypes rs12785878 (1.31, 1.00-1.70) and rs2282679 (2.08, 1.66-2.60) increased odds of hypovitaminosis. Hypovitaminosis D was common also when recommended dietary intake was obtained (men 29%, women 24%). CONCLUSION: Several factors were associated with hypovitaminosis D. The condition was common even when recommended vitamin D intake was reported. The results support the importance of vitamin D fortification and nutrient supplement use.


Asunto(s)
Enfermedades Cardiovasculares/sangre , Deficiencia de Vitamina D/sangre , Vitamina D/análogos & derivados , Adulto , Alelos , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/genética , Anticonceptivos Orales/efectos adversos , Estudios Transversales , Dieta , Suplementos Dietéticos , Femenino , Finlandia/epidemiología , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Prevalencia , Factores de Riesgo , Estaciones del Año , Vitamina D/administración & dosificación , Vitamina D/sangre , Vitamina D/genética , Deficiencia de Vitamina D/epidemiología , Deficiencia de Vitamina D/genética , Deficiencia de Vitamina D/patología
10.
Orv Hetil ; 156(1): 28-31, 2015 Jan 04.
Artículo en Húngaro | MEDLINE | ID: mdl-25544052

RESUMEN

INTRODUCTION: Vulvovaginal candidiasis is the most common mycosis, however, the available information about antifungal susceptibilities of these yeasts is limited. AIM: To compare the gold standard fungal culture with a new molecular identification method and report the incidence of yeast species in vulvovaginitis candidosa. METHOD: The authors studied 370 yeasts isolated from vulvovaginal candidiasis and identified them by phenotypic and molecular methods. RESULTS: The most common species was Candida albicans (85%), followed by Candida glabrata, and other Candida species. CONCLUSION: At present there are no recommendations for the evaluation of antifungal susceptibility of pathogenic fungal species occurring in vulvovaginal candidiasis and the natural antifungal resistance of the different species is known only. Matrix Assisted Laser Desorption Ionization Time of Flight identification can be used to differentiate the fluconazole resistant Candida dubliniensis and the sensitive Candida albicans strains.


Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidiasis Vulvovaginal/diagnóstico , Candidiasis Vulvovaginal/tratamiento farmacológico , Administración Intravaginal , Administración Oral , Adulto , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antifúngicos/administración & dosificación , Candida albicans/aislamiento & purificación , Candida glabrata/aislamiento & purificación , Candida tropicalis/aislamiento & purificación , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/efectos adversos , Complicaciones de la Diabetes/microbiología , Femenino , Fluconazol/uso terapéutico , Humanos , Hungría , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo
11.
Cancer Res ; 74(15): 4078-89, 2014 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-25085875

RESUMEN

Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U.S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER(+); OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER(-)) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; Pheterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks.


Asunto(s)
Neoplasias de la Mama/epidemiología , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/química , Adulto , Neoplasias de la Mama/inducido químicamente , Estudios de Casos y Controles , Anticonceptivos Orales/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , Factores de Riesgo , Estados Unidos/epidemiología , Adulto Joven
12.
BMC Complement Altern Med ; 14: 222, 2014 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-24996447

RESUMEN

BACKGROUND: Endometriosis affects fertility negatively. The study aims to evaluate whether laparoscopic surgery combined with oral contraceptive or herbs were more effective than laparoscopic alone in improving fecundity and pelvic pain in women with minimal/mild endometriosis. METHODS: A randomized controlled trial (RCT) was conducted in 156 infertile women with minimal/mild endometriosis. After laparoscopic surgery, patients were randomized to three groups: in Group A (n = 52) oral contraceptive (OC) was administered one pill a day, continuous for 63 days without intervals, in Group B (n = 52) OC was administered as above and then Dan'e mixture was added 30 g/day for the latter 30 days, and in control Group C (n = 52) patients tried to get pregnant after surgery without complementary treatment. The follow-up periods were 12 months in Group C and 14 months in complementary medical treatment Group A and B. The pregnant women were further followed up, and labor and pregnancy outcomes were assessed. Primary outcome was pregnancy rate (PR) and live birth rate (LBR). Secondary outcomes included changes of pelvic pain visual analog scale scores and side effects. Analyses were done as intention-to-treat. RESULTS: The PR was 46.80% (73/156), and the LBR was 69.86% (51/73). Of the 73 pregnancies, 60 occurred within 12 months of follow-up and 7 of the remaining 13 patients underwent assisted reproductive technology for >1 year. No significant difference was observed in PR and LBR among the three groups. Patients given medical treatment (OCs or OCs plus herbal medicine) had significantly decreased pain scores compared with the laparoscopy alone group. CONCLUSIONS: Combination of laparoscopy with OCs or OCs and herbal medicine does not have more advantages than laparoscopy alone in improving fertility of women with minimal/mild endometriosis. TRIAL REGISTRATION: ChiCTR-TRC-11001820.


Asunto(s)
Anticonceptivos Orales/administración & dosificación , Medicamentos Herbarios Chinos/administración & dosificación , Endometriosis/tratamiento farmacológico , Infertilidad Femenina/tratamiento farmacológico , Dolor Pélvico/tratamiento farmacológico , Adulto , Terapia Combinada , Anticonceptivos Orales/efectos adversos , Medicamentos Herbarios Chinos/efectos adversos , Endometriosis/complicaciones , Endometriosis/cirugía , Femenino , Fertilidad , Humanos , Infertilidad Femenina/etiología , Infertilidad Femenina/cirugía , Laparoscopía , Dolor Pélvico/etiología , Dolor Pélvico/cirugía , Embarazo , Resultado del Embarazo , Estudios Prospectivos , Adulto Joven
13.
High Blood Press Cardiovasc Prev ; 21(3): 221-6, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24728953

RESUMEN

INTRODUCTION: One of the most frequent side effect of oral contraceptives use is a stable alteration of the lipid profile. This could be even more relevant in women affected by polycystic ovary syndrome (PCOS). AIM: Considering the importance of a balanced lipid profile in cardiovascular prevention and that the exposure to the drugs could be many years long, our aim was to investigate the possible beneficial effect of a largely tested low-dosed combined lipid-lowering nutraceutical on dyslipidemias induced by oestroprogestins prescribed to young women for different indications. METHODS: We prospectively enrolled 84 patients in primary cardiovascular disease prevention, with low estimated cardiovascular disease risk (<5 % according to the ESC/EAS guidelines), and LDL-C increased above normal value (LDL-C >130 mg/dL) after the use of at least two different oral oestroprogestins treatments. Forty-four women were prescribed oral oestroprogestins for PCOS, while 40 for pure contraception. The tested nutraceutical contained berberine 500 mg/tab and monacolins 3 mg/tab was prescribed to all enrolled patients, associated the previously prescribed standard lipid-lowering diet. RESULTS: After 3 months of nutraceutical treatment, we observed a significant improvement in BMI (-1.5 ± 0.8 %, p < 0.001), FPG (-6.9 ± 5.8 %, p < 0.001), HOMA index (-3.5 ± 5.6 %, p < 0.001), TC (-20.1 ± 6.6 %, p < 0.001), LDL-C (-25.3 ± 8.9 %, p < 0.001), HDL-C (+14.1 ± 2.2 %, p < 0.001), TG (-29.9 ± 25.2 %, p < 0.001) and hsCRP (-2.5 ± 2.4 %, p = 0.019). Similar results have been obtained even repeating the analysis by subgroups, beyond hsCRP that significantly improved in PCOS patients compared to both the baseline and the non-PCOS group. CONCLUSION: It appears that the tested combined lipid-lowering nutraceutical is able to equally improve lipid metabolism in oral contraceptive induced hypercholesterolemia in women affected or not by PCOS.


Asunto(s)
Berberina/uso terapéutico , Enfermedades Cardiovasculares/epidemiología , Anticonceptivos Orales/efectos adversos , Etinilestradiol/efectos adversos , Hipercolesterolemia/inducido químicamente , Lovastatina/uso terapéutico , Norpregnenos/efectos adversos , Adulto , Anticolesterolemiantes/farmacología , Anticolesterolemiantes/uso terapéutico , Berberina/farmacología , Enfermedades Cardiovasculares/prevención & control , Anticoncepción/métodos , Anticonceptivos Orales/uso terapéutico , Suplementos Dietéticos , Combinación de Medicamentos , Etinilestradiol/uso terapéutico , Femenino , Humanos , Hipercolesterolemia/complicaciones , Hipercolesterolemia/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Lovastatina/farmacología , Norpregnenos/uso terapéutico , Proyectos Piloto , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento
14.
Phytomedicine ; 20(13): 1186-9, 2013 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-23928507

RESUMEN

A case of autoimmune liver hepatitis is reported: the onset was triggered by consumption of green tea infusion in a patient taking oral contraceptives and irbesartan. We hypothesize that our patient, carrying genetic variant of hepatic metabolism making her particularly susceptible to oxidative stress, developed an abnormal response to a mild toxic insult, afforded by a combination of agents (oral contraceptives+irbesartan+green tea) that normally would not be able to cause damage. Her particular hepatic metabolism further increased the drugs' concentration, favoring the haptenization of liver proteins, eventually leading to the development of an autoimmune hepatitis.


Asunto(s)
Compuestos de Bifenilo/efectos adversos , Anticonceptivos Orales/efectos adversos , Hepatitis Autoinmune/genética , Polimorfismo de Nucleótido Simple/genética , Té/efectos adversos , Tetrazoles/efectos adversos , Adulto , Femenino , Hepatitis Autoinmune/diagnóstico , Hepatitis Autoinmune/tratamiento farmacológico , Humanos , Irbesartán , Hígado/efectos de los fármacos , Estrés Oxidativo
15.
Hum Reprod ; 28(9): 2372-80, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23800622

RESUMEN

STUDY QUESTION: What is the effect of estrogen on heparanase procogulant activity? SUMMARY ANSWER: Estrogen increases heparanase procoagulant activity. WHAT IS KNOWN ALREADY: Estrogen therapy increases the risk of thrombosis and was previously found to up-regulate heparanase expression. Heparanase is involved in angiogenesis and metastasis, and has been shown to form a complex with tissue factor (TF) and also shown to enhance the generation of factor Xa. STUDY DESIGN, SIZE, DURATION: A case-control study. Thirty-four healthy women using oral contraceptives (OC) and 41 women not using hormonal therapy and not pregnant per history were enrolled, over a 5-month period, at the Rambam Medical Center, Haifa, Israel. In vitro, estrogen receptor-positive (MCF-7) and -negative (MDA-231) cell lines were incubated with estrogen, tamoxifen and ICI-182.780 a pure estrogen receptor antagonist. The cell medium was evaluated for TF/heparanase complex activity, TF activity and heparanase procoagulant activity by chromogenic substrate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Exclusion criteria included age <18 years, post-menopausal women, concomitant medications other than supplement minerals and vitamins, acute or chronic illness. MAIN RESULTS AND THE ROLE OF CHANCE: The study demonstrates increased risk of high heparanase procoagulant activity in OC users. When a cutoff level of 0.25 (absorbance 405-490 nm) was set, the odds ratio was 131 (P < 0.0001). When all results were studied by quartiles, in quartiles 3 and 4 the results were almost exclusively of the OC users (P < 0.0001). In cell cultures, estrogen and tamoxifen increased heparanase procoagulant activity in the medium of estrogen receptor-positive (MCF-7) cells. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the current study is that the two estrogens given to the women and cell cultures, ethinyl estradiol (EE) and 17-ß-estradiol (E2), respectively, may have different effects on the coagulation system, although an increase in heparanase procoagulant activity was demonstrated in both of them. Although the sample size of the study group was limited, significant differences in the activation of the extrinsic coagulation pathway were demonstrated. WIDER IMPLICATIONS OF THE FINDINGS: The clinical relevance of the heparanase procoagulant activity assay as a screening tool in thrombophilia work-up should further be elucidated.


Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Anticonceptivos Orales/efectos adversos , Glucuronidasa/sangre , Trombofilia/inducido químicamente , Adulto , Estudios de Casos y Controles , Línea Celular , Estradiol/efectos adversos , Estradiol/análogos & derivados , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Estrógenos/efectos adversos , Estrógenos/farmacología , Femenino , Fulvestrant , Glucuronidasa/metabolismo , Humanos , Israel/epidemiología , Glándulas Mamarias Humanas/efectos de los fármacos , Glándulas Mamarias Humanas/metabolismo , Receptores de Estrógenos/agonistas , Receptores de Estrógenos/antagonistas & inhibidores , Receptores de Estrógenos/metabolismo , Riesgo , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Transducción de Señal/efectos de los fármacos , Tamoxifeno/efectos adversos , Tamoxifeno/farmacología , Trombofilia/sangre , Trombofilia/epidemiología , Trombofilia/metabolismo , Tromboplastina/metabolismo , Adulto Joven
16.
Contraception ; 86(1): 62-6, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22494786

RESUMEN

BACKGROUND: Oral contraceptives (OCs) may affect oxidative stress status. We aimed to assess whether supplementation with vitamins E and C reduced this OC effect. STUDY DESIGN: One hundred twenty healthy female individuals were divided into three groups: A, control; B, untreated OCU (OC users); and C, treated OCU (OC users with vitamin E and C supplementation). In all cases, plasma glutathione peroxidase (GPx) and glutathione reductase (GR) activities and malondialdehyde (MDA) level were determined. RESULTS: Significant increases were found in the plasma MDA level, and activities of GPx and GR in plasma were decreased in Group B compared to the control group. Supplementation with vitamin C and E significantly increased the activity of GPx and GR activity, and reduced plasma MDA levels in Group C (p<.05). CONCLUSIONS: These data suggest that low-dose OCs, by enhancing the stress oxidative and lipid peroxidation, may represent a potential cardiovascular risk factor, and the use of vitamins E and C may be beneficial in ameliorating this side effect of OCs.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Suplementos Dietéticos , Glutatión Peroxidasa/sangre , Glutatión Reductasa/sangre , Peroxidación de Lípido/efectos de los fármacos , Vitaminas/farmacología , Adulto , Ácido Ascórbico/farmacología , Femenino , Humanos , Malondialdehído/sangre , Estrés Oxidativo/efectos de los fármacos , Vitamina E/farmacología
17.
Presse Med ; 40(3): 279-86, 2011 Mar.
Artículo en Francés | MEDLINE | ID: mdl-21216127

RESUMEN

The enzyme-inducing antiepileptic drugs such as carbamazepine, phenytoin, barbiturates, oxcarbazepine do not allow oral contraceptives. The pregnancy must be planned. Every patient in childbearing age should be informed by her practitioner. The rule is to optimize the antiepileptic treatment before the pregnancy: less drugs, less dosages. This optimization will depend on the epileptic syndrome and the nature of the treatment. Valproate of sodium should be avoided, if possible, during pregnancy. Preconceptional supplementation by folic acid should be considered. Antiepileptic drugs monitoring is required during pregnancy. Natural delivery with peridural anaesthesiology is mandatory. The breast feeding must be considered individually.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/efectos adversos , Epilepsia/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Anomalías Inducidas por Medicamentos/etiología , Anomalías Inducidas por Medicamentos/prevención & control , Anestesia Epidural , Anestesia Obstétrica , Encéfalo/efectos de los fármacos , Lactancia Materna , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Monitoreo de Drogas , Quimioterapia Combinada , Electroencefalografía/efectos de los fármacos , Epilepsia/etiología , Servicios de Planificación Familiar , Femenino , Humanos , Recién Nacido , Embarazo , Complicaciones del Embarazo/etiología , Factores de Riesgo , Procesamiento de Señales Asistido por Computador
18.
Orv Hetil ; 151(28): 1132-6, 2010 Jul 11.
Artículo en Húngaro | MEDLINE | ID: mdl-20570793

RESUMEN

Chronic B and C virus hepatitis (HBV and HCV) are the most important risk factors in the development of hepatocellular carcinoma (HCC). About 40-50% of HCC is induced by these two chronic viral infections. Prevalence of HCC is slowly increasing in the United States and in Western-Europe, whereas alcohol consumption is gradually decreasing in the majority of these countries. However, the most important environmental risk factor for HCC is still the heavy long-term alcohol use. The risk of cirrhosis and HCC increases linearly, wherever ethanol intake is greater than 60 g/day for men and women. Aflatoxin, which contaminates grains, mostly in China and Africa, is a well-known mycotoxin. Since geographical distribution of aflatoxin as well as HBV overlaps with each other, they have a synergistic effect on inducing HCC. Cigarette smoking has also hepatocarcinogenic effect, which is significantly enhanced by the concomitant alcohol use or chronic viral hepatitis. Obesity, non-alcoholic fatty liver and steatohepatitis as well as diabetes mellitus together also form a significant risk for HCC, due to the gradually increasing number of patients. Insulin resistance and oxidative stress are the major pathogenetic mechanisms leading to hepatic cell injury in these patients. Oral contraceptive drugs may also play a role in the development of HCC. The long-term exposure to organic solvents is also a risk factor for HCC. Dietary antioxidants, selenium, statins and coffee drinking have protective effect against HCC.


Asunto(s)
Carcinoma Hepatocelular/etiología , Neoplasias Hepáticas/etiología , Aflatoxinas/efectos adversos , Consumo de Bebidas Alcohólicas/efectos adversos , Consumo de Bebidas Alcohólicas/epidemiología , Antioxidantes/administración & dosificación , Cafeína/administración & dosificación , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/prevención & control , Carcinoma Hepatocelular/virología , Café , Anticonceptivos Orales/efectos adversos , Complicaciones de la Diabetes , Exposición a Riesgos Ambientales/efectos adversos , Europa (Continente)/epidemiología , Hígado Graso/complicaciones , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/epidemiología , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/epidemiología , Humanos , Resistencia a la Insulina , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/prevención & control , Neoplasias Hepáticas/virología , Obesidad/complicaciones , Estrés Oxidativo , Prevalencia , Factores de Riesgo , Fumar/efectos adversos , Fumar/epidemiología , Solventes/toxicidad , Estados Unidos/epidemiología
19.
Transfus Med ; 18(6): 360-5, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19140819

RESUMEN

Iron depletion is a well-known side effect of blood donation. Research evidence also suggests an increasing prevalence of vitamin deficiency in apparently healthy subjects, but there is little information regarding the relationship between blood donation and vitamin status. A total of 217 volunteers (80 first-time and 137 repeat blood donors) were consecutively enrolled in the study. All subjects completed self-administered medical history and food intake forms, which included questions regarding alcohol consumption and smoking as well as on vitamin supplement, iron and contraceptive use (females). Vitamin B6, folic acid, vitamin B12 and biotin levels were measured using standard techniques. The mean vitamin levels of first-time and repeat blood donors did not significantly differ. Vitamin deficiencies occurred in both first-time and repeat blood donors but not on vitamin supplements. Vitamin status was affected by alcohol, nicotine and contraceptives. Blood donation does not decrease the level of water-soluble vitamins. Vitamin deficiencies occur in apparently healthy first-time as well as in repeat blood donors and can be prevented by vitamin supplementation.


Asunto(s)
Avitaminosis/etiología , Donantes de Sangre , Suplementos Dietéticos , Vitaminas/sangre , Vitaminas/uso terapéutico , Adulto , Consumo de Bebidas Alcohólicas/sangre , Consumo de Bebidas Alcohólicas/epidemiología , Ácido Ascórbico/administración & dosificación , Avitaminosis/sangre , Avitaminosis/prevención & control , Biotina/administración & dosificación , Anticonceptivos Orales/efectos adversos , Anticonceptivos Orales/farmacología , Femenino , Compuestos Ferrosos/administración & dosificación , Ácido Fólico/administración & dosificación , Humanos , Masculino , Fumar/efectos adversos , Fumar/epidemiología , Vitamina B 12/administración & dosificación , Vitamina B 6/administración & dosificación , Complejo Vitamínico B/sangre
20.
Hum Reprod ; 22(8): 2335-43, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17584753

RESUMEN

BACKGROUND: Oxidative stress is associated with the development of several disorders including cardiovascular disease and cancer. Among conditions known to influence oxidative stress, the use of oral contraception (OC) in women has been a matter of ongoing discussion. METHODS: A total of 897 eligible and healthy volunteers were recruited from among the patients of 50 general practitioners participating in the ELAN study (Etude Liégeoise sur les ANtioxydants). A subsample consisting of 209 women aged 40-48 years was studied for a comprehensive oxidative stress status (OSS), including the analysis of antioxidants, trace elements and three markers of oxidative damage to lipids. Among 209 subsample, 49 (23%) were OC users (OCU), 119 (57%) non-contraception users (NCU) and 41 (20%) were intrauterine (hormonal and copper) devices users (IUD). RESULTS: After adjustment for smoking, systolic and diastolic blood pressure and BMI (or waist circumference), a marked and significant increase in lipid peroxides was observed among OCU women when compared with NCU and IUD users. A cut-off value of 660 microM in lipid peroxides allowed the discrimination of OCU from the two other groups. In contrast, no difference was observed in the plasma concentration of both oxidized low-density lipoprotein (LDL) and their related antibodies. The increased level in lipid peroxides was strongly related to higher concentrations of copper (r < 0.84; P < 0.0001, cut-off value 1.2 mg/l). When compared with NCU and IUD users, plasma antioxidant defences were significantly altered in OCU women as shown by lower levels of beta-carotene (decrease of 39%; P < 0.01) and gamma-tocopherol (decrease by 22%; P < 0.01). In contrast, higher concentrations of selenium (increased by 11.8%; P < 0.01) were observed in OCU women. Blood concentrations of vitamin C, alpha-tocopherol and zinc were unaffected by OC use. CONCLUSIONS: The intake of OC significantly increases the lipid peroxidation in women aged 40-48 years. This may represent a potential cardiovascular risk factor for these women.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Estrés Oxidativo/efectos de los fármacos , Adulto , Antioxidantes/análisis , Enfermedades Cardiovasculares/etiología , Cobre/sangre , Femenino , Humanos , Dispositivos Intrauterinos de Cobre , Dispositivos Intrauterinos Medicados , Peroxidación de Lípido/efectos de los fármacos , Peróxidos Lipídicos/sangre , Lipoproteínas LDL/sangre , Lipoproteínas LDL/inmunología , Persona de Mediana Edad , Factores de Riesgo , Selenio/sangre , beta Caroteno/sangre , gamma-Tocoferol/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA